Managing complex perianal disease after anti-TNF failure: Where to go next? - ScienceDirect
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial - The Lancet Gastroenterology & Hepatology
European Crohn´s and Colitis Organisation - ECCO - Volume 14, Issue 2
Frontiers | Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
Biomedicines | Free Full-Text | The New Proactive Approach and Precision Medicine in Crohn's Disease
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology
European Crohn´s and Colitis Organisation - ECCO - OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug
Adalimumab | ECCO E-Guide
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease - Gastroenterology
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator | Scientific Reports
JCM | Free Full-Text | The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy - Gastroenterology
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay | Science Translational Medicine
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? | Nature Reviews Gastroenterology & Hepatology
Adalimumab | ECCO E-Guide
Children | Free Full-Text | Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)—A Narrative Review
Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis | European Journal of Medical Research | Full Text
Cureus | Use of Azathioprine in Ulcerative Colitis: A Comprehensive Review | Article
PDF) Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease | NEJM
No Difference in Disease Markers for IBD Patients Treated With Biosimilars | MedPage Today
PDF) P553 Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week
